FDA has been working on inclusivity of clinical trials. But as today's hearing is demonstrating, there's still a lot of patients desperate for access to drugs still in development that cannot get access.
Highlighting the ongoing challenges patients face in accessing drugs under development.
Share
More from Cathy McMorris Rodgers
I move that the committee do now recess and reconvene in executive session based on our determination that the disclosure of matters that need to be considered during this hearing would (1) endanger national security and (2) compromise…
Thank you, Mr. Chairman. Thank you again for bringing the field hearing to eastern Washington, and to all who have testified.
I was disappointed to hear that certain restrictions in NTIA's Notice of Funding Opportunity would lead to funds being primarily spent laying extensive fiber.
I firmly believe that we must do what we can now to safeguard Americans' personal data while we work to advance privacy legislation.
Other voices in this conversation
